Zhao Binsheng, Schwartz Lawrence H, Moskowitz Chaya S, Ginsberg Michelle S, Rizvi Naiyer A, Kris Mark G
Department of Medical Physics and Radiology, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA.
Radiology. 2006 Dec;241(3):892-8. doi: 10.1148/radiol.2413051887.
To prospectively quantify tumor response or progression in patients with lung cancer by using thin-section computed tomography (CT) and a semiautomated algorithm to calculate tumor volume and other parameter values.
This HIPAA-compliant study was institutional review board approved; informed patient consent was waived. CT scans of 15 measurable non-small cell lung cancers (in five men and 10 women; mean age, 64 years; range, 38-78 years) before and after gefitinib treatment were analyzed. A semiautomated three-dimensional lung cancer segmentation algorithm was developed and applied to each tumor at baseline and follow-up. The computer calculated the greatest diameter (unidimensional measurement), the product of the greatest diameter and the greatest perpendicular diameter (bidimensional measurement), and the volume of each tumor. Exact McNemar tests were used to analyze differences in the percentage change calculated with different measurement techniques.
The computer accurately segmented 14 of the 15 tumors. One paramediastinal tumor required manual separation from the mediastinum. Eleven (73%) of the 15 patients had an absolute change in tumor volume of at least 20%, compared with one (7%) and four (27%) patients who had similar changes in unscaled unidimensional (P < .01) and bidimensional (P = .04) tumor measurements, respectively. Seven (47%) patients had an absolute change in tumor volume of at least 30%. In contrast, at unscaled analysis, no patients at unidimensional measurement (P = .02) and two (13%) patients at bidimensional measurement (P = .06) had a change of at least 30%.
Compared with the unidimensional and bidimensional techniques, semiautomated tumor segmentation enabled the identification of a larger number of patients with absolute changes in tumor volume of at least 20% and 30%.
通过使用薄层计算机断层扫描(CT)和半自动算法来计算肿瘤体积及其他参数值,对肺癌患者的肿瘤反应或进展进行前瞻性定量分析。
本研究符合健康保险流通与责任法案(HIPAA)要求,经机构审查委员会批准;患者知情同意书被豁免。分析了15例可测量的非小细胞肺癌患者(5例男性,10例女性;平均年龄64岁;范围38 - 78岁)在吉非替尼治疗前后的CT扫描图像。开发了一种半自动三维肺癌分割算法,并将其应用于基线和随访时的每个肿瘤。计算机计算每个肿瘤的最大直径(一维测量)、最大直径与最大垂直直径的乘积(二维测量)以及体积。采用精确的McNemar检验分析不同测量技术计算的百分比变化差异。
计算机准确分割了15个肿瘤中的14个。一个纵隔旁肿瘤需要手动与纵隔分离。15例患者中有11例(73%)肿瘤体积绝对变化至少20%,相比之下,未缩放的一维(P <.01)和二维(P =.04)肿瘤测量中分别只有1例(7%)和4例(27%)患者有类似变化。7例(47%)患者肿瘤体积绝对变化至少30%。相比之下,在未缩放分析中,一维测量时无患者(P =.02),二维测量时有2例(13%)患者变化至少30%。
与一维和二维技术相比,半自动肿瘤分割能够识别出更多肿瘤体积绝对变化至少20%和30%的患者。